Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.52 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 5/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1278421 | 1.00 | PAOX (0.52) | PAOXTBXAS1HTR7HTR1ACYP1A2 | |
| SCHEMBL1285997 | 1.00 | PAOX (0.52) | PAOXTBXAS1HTR7HTR1ACYP1A2 | |
| SCHEMBL10597308 | 1.00 | PAOX (0.52) | PAOXTBXAS1HTR7HTR1ACYP1A2 | |
| SCHEMBL10597081 | 1.00 | PAOX (0.52) | PAOXTBXAS1HTR7HTR1ACYP1A2 | |
| SCHEMBL1285649 | 0.98 | PAOX (0.48) | PAOXTBXAS1HTR7HTR1ACYP1A2 | |
| SCHEMBL504157 | 0.92 | SMN1; SMN2 (0.50) | PAOXTBXAS1HTR7HTR1ACYP1A2 | |
| SCHEMBL7113039 | 0.86 | SMN1; SMN2 (0.60) | PAOXTBXAS1HTR1ACYP1A2MAPK1 | |
| SCHEMBL1275571 | 0.84 | SMN1; SMN2 (0.62) | TBXAS1HTR1ACYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL6473449 | 0.83 | GLA (0.42) | PAOXTBXAS1HTR7HTR1ACYP1A2 | |
| SCHEMBL19412256 | 0.82 | SMN1; SMN2 (0.66) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598937-B1 | AMPHIPHILIC POLYSILOXANE PREPOLYMERS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-29 | — | — | EP | claimed |
| US-20120088861-A1 | WATER-PROCESSABLE SILICONE-CONTAINING PREPOLYMERS AND USES THEREOF | ALCON INC. (CH) | 2012-04-12 | — | — | US | claimed |
| US-20120029111-A1 | AMPHIPHILIC POLYSILOXANE PREPOLYMERS AND USES THEREOF | ALCON INC. (CH) | 2012-02-02 | — | — | US | claimed |
| US-9684095-B2 | Hydrophilized carbosiloxane vinylic monomers | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-9500775-B2 | Actinically-crosslinkable amphiphilic prepolymers | NOVARTIS AG (CH) | 2016-11-22 | — | — | US | disclosed |
| US-9422447-B2 | Azetidinium-containing copolymers and uses thereof | NOVARTIS AG (CH) | 2016-08-23 | — | — | US | disclosed |
| US-9261626-B2 | Contact lenses with enzymatically degradable coatings thereon | NOVARTIS AG (CH) | 2016-02-16 | — | — | US | disclosed |
| US-9244195-B2 | Silicone hydrogel lenses with nano-textured surfaces | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150369962-A1 | ACTINICALLY-CROSSLINKABLE AMPHIPHILIC PREPOLYMERS | ALCON INC. (CH) | 2015-12-24 | — | — | US | disclosed |
| US-9187601-B2 | Water-processable silicone-containing prepolymers and uses thereof | NOVARTIS AG (CH) | 2015-11-17 | — | — | US | disclosed |
| US-20150309210-A1 | HYDROPHILIZED CARBOSILOXANE VINYLIC MONOMERS | ALCON INC. (CH) | 2015-10-29 | — | — | US | disclosed |
| US-8557940-B2 | Amphiphilic polysiloxane prepolymers and uses thereof | NOVARTIS AG (CH) | 2013-10-15 | — | — | US | disclosed |
| US-20130148077-A1 | CONTACT LENSES WITH ENZYMATICALLY DEGRADABLE COATINGS THEREON | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-20130095235-A1 | METHOD FOR MAKING UV-ABSORBING OPHTHALMIC LENSES | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-20120314185-A1 | SILICONE HYDROGEL LENSES WITH NANO-TEXTURED SURFACES | ALCON INC. (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120088844-A1 | CHAIN-EXTENDED POLYSILOXANE CROSSLINKERS WITH DANGLING HYDROPHILIC POLYMER CHAINS | ALCON INC. (CH) | 2012-04-12 | — | — | US | disclosed |
| US-20120088843-A1 | POLYMERIZABLE CHAIN-EXTENDED POLYSILOXANES WITH PENDANT HYDROPHILIC GROUPS | ALCON INC. (CH) | 2012-04-12 | — | — | US | disclosed |
| US-20120088861-A1 | WATER-PROCESSABLE SILICONE-CONTAINING PREPOLYMERS AND USES THEREOF | ALCON INC. (CH) | 2012-04-12 | — | — | US | disclosed |
| US-20120029111-A1 | AMPHIPHILIC POLYSILOXANE PREPOLYMERS AND USES THEREOF | ALCON INC. (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20110063567-A1 | PREPOLYMERS SUITABLE FOR MAKING ULTRA-VIOLET ABSORBING CONTACT LENSES | ALCON INC. (CH) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088843-A1 | POLYMERIZABLE CHAIN-EXTENDED POLYSILOXANES WITH PENDANT HYDROPHILIC GROUPS | GFER, DRD1, SORD | PAOX 1210/4885TBXAS1 3695/4885HTR7 1507/4885 |
| US-20120029111-A1 | AMPHIPHILIC POLYSILOXANE PREPOLYMERS AND USES THEREOF | PIGS, ELOVL1, HACD2 | PAOX 333/4885TBXAS1 3701/4885HTR7 3508/4885 |
| US-20150309210-A1 | HYDROPHILIZED CARBOSILOXANE VINYLIC MONOMERS | VCL, MACF1, HCAR1 | PAOX 295/4885TBXAS1 1697/4885HTR7 468/4885 |
| US-20120088844-A1 | CHAIN-EXTENDED POLYSILOXANE CROSSLINKERS WITH DANGLING HYDROPHILIC POLYMER CHAINS | HACD2, HACD3, PCNA | PAOX 287/4885TBXAS1 4595/4885HTR7 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.